Display options
Cite
Del Rosso JQ, Tanghetti E. Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence. J Clin Aesthet Dermatol. 2021;14(3):32-37
Del Rosso, J. Q., & Tanghetti, E. (2021). Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence. The Journal of clinical and aesthetic dermatology, 14(3), 32-37.
Del Rosso, James Q, and Tanghetti, Emil. "Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence." The Journal of clinical and aesthetic dermatology vol. 14,3 (2021): 32-37.
Del Rosso JQ, Tanghetti E. Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence. J Clin Aesthet Dermatol. 2021 Mar;14(3):32-37. Epub 2021 Mar 01. PMID: 33841614; PMCID: PMC8021401.
Copy Download .nbib Format: NLM
Share it on

J Clin Aesthet Dermatol. 2021 Mar;14(3):32-37. Epub 2021 Mar 01.

Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence.

The Journal of clinical and aesthetic dermatology

James Q Del Rosso, Emil Tanghetti

Affiliations

  1. Dr. Del Rosso is Research Director at JDR Dermatology Research in Las Vegas, Nevada, is with Thomas Dermatology in Las Vegas, Nevada, and is an adjunct clinical professor of dermatology at Touro University Nevada in Henderson, Nevada.
  2. Dr. Tanghetti is with the Center for Dermatology and Laser Surgery in Sacramento, California.

PMID: 33841614 PMCID: PMC8021401

[No abstract available.]

Copyright © 2020. Matrix Medical Communications. All rights reserved.

Keywords: Adrenergic alpha-1 receptor agonists; adrenergic receptor agonists; adrenoceptors; erythema; erythematotelangiectatic rosacea; oxymetazoline; rosacea; topical administration; vasoconstriction; vasoconstrictor agents

Conflict of interest statement

FUNDING:This work was funded by Aclaris Therapeutics, Inc. and EPI Health, LLC. DISCLOSURES:Dr. Del Rosso is a consultant for Almirall, BiopharmX, EPI Health, Evommune, Galderma, Bausch Health (Ortho

References

  1. Brain Behav Immun. 1993 Jun;7(2):154-63 - PubMed
  2. Exp Dermatol. 2018 Jul;27(7):763-768 - PubMed
  3. Eur J Pharmacol. 2003 Apr 25;467(1-3):223-31 - PubMed
  4. J Drugs Dermatol. 2018 Jan 1;17(1):97-105 - PubMed
  5. J Drugs Dermatol. 2018 Mar 1;17(3):290-298 - PubMed
  6. J Clin Aesthet Dermatol. 2017 Jul;10(7):28-32 - PubMed
  7. J Clin Aesthet Dermatol. 2012 Mar;5(3):26-36 - PubMed
  8. Br J Dermatol. 2019 May;180(5):1050-1057 - PubMed
  9. Lasers Surg Med. 2021 Jan;53(1):55-65 - PubMed
  10. J Dermatol Sci. 2009 Aug;55(2):77-81 - PubMed
  11. J Dermatol Sci. 2014 Jul;75(1):49-54 - PubMed
  12. J Am Acad Dermatol. 2018 Sep;79(3):e57-e59 - PubMed
  13. Dermatol Ther (Heidelb). 2015 Jun;5(2):117-27 - PubMed
  14. Acta Derm Venereol. 2015 Apr;95(4):395-400 - PubMed
  15. J Pharmacol Sci. 2009 Jul;110(3):276-84 - PubMed
  16. Lasers Surg Med. 2020 Jan;52(1):38-43 - PubMed
  17. J Am Acad Dermatol. 2018 Jun;78(6):1156-1163 - PubMed
  18. Exp Dermatol. 2007 Mar;16(3):171-8 - PubMed
  19. J Cell Sci. 2001 Oct;114(Pt 19):3557-64 - PubMed
  20. J Pharmacol Exp Ther. 2006 Feb;316(2):843-51 - PubMed
  21. Cutis. 2014 Mar;93(3):134-8 - PubMed
  22. J Clin Invest. 2007 Mar;117(3):803-11 - PubMed
  23. J Am Acad Dermatol. 2013 Dec;69(6 Suppl 1):S44-56 - PubMed
  24. J Drugs Dermatol. 2018 Feb 1;17(2):213-220 - PubMed
  25. Arch Dermatol. 2007 Nov;143(11):1369-71 - PubMed
  26. Invest Ophthalmol Vis Sci. 2011 Jul 20;52(8):5424-31 - PubMed
  27. J Investig Dermatol Symp Proc. 2011 Dec;15(1):2-11 - PubMed
  28. Lasers Surg Med. 2020 Jan;52(1):17-22 - PubMed
  29. Br J Dermatol. 2017 Feb;176(2):431-438 - PubMed
  30. J Drugs Dermatol. 2018 Jun 1;17(6):621-626 - PubMed
  31. Pharmacol Rev. 2001 Jun;53(2):319-56 - PubMed
  32. Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1044-51 - PubMed
  33. J Pharmacol Exp Ther. 1985 Feb;232(2):395-400 - PubMed
  34. Cutis. 2014 Feb;93(2):71-6 - PubMed
  35. Exp Dermatol. 2017 Nov;26(11):1143-1145 - PubMed
  36. Int J Mol Sci. 2016 Sep 15;17(9): - PubMed
  37. J Drugs Dermatol. 2017 Sep 1;16(9):909-916 - PubMed
  38. Cutis. 2009 Jul;84(1):43-7 - PubMed
  39. J Am Acad Dermatol. 2002 Apr;46(4):584-7 - PubMed
  40. Acta Derm Venereol. 2016 Jun 15;96(5):579-86 - PubMed
  41. J Drugs Dermatol. 2018 Mar 1;17(3):308-316 - PubMed

Publication Types